Cutler Group’s Bicycle Therapeutics BCYC Stock Holding History

Cutler Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,100	Closed	-$2K	–	4966
2022 Q1	$2K	Buy	+10,100	New	+$472K	﹤0.01%	4619

Other funds holding BCYC

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cutler Group's BCYC Position: Q4 2023 in Review

Cutler Group sold out of Bicycle Therapeutics (BCYC) in Q4 2023, closing a stake of 2,400 shares — an estimated $48K sold.

Cutler Group first reported a position in BCYC in Q3 2021 and held it in 9 quarters. The position peaked at $608K in Q3 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

Cutler Group reported no remaining Bicycle Therapeutics position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 2,400 Bicycle Therapeutics shares in Q4 2023, an estimated $48K.
Cutler Group first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 9 quarters.
Cutler Group's Bicycle Therapeutics position peaked at $608K in Q3 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.